Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Sorbonne Université · Université Sorbonne Paris Nord · +2 more institutions
Abstract
Understanding the health consequences associated with exposure to risk factors is necessary to inform public health policy and practice. To systematically quantify the contributions of risk factor exposures to specific health outcomes, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 aims to provide comprehensive estimates of exposure levels, relative health risks, and attributable burden of disease for 88 risk factors in 204 countries and territories and 811 subnational locations, from 1990 to 2021.
The GBD 2021 risk factor analysis used data from 54 561 total distinct sources to produce epidemiological estimates for 88 risk factors and their associated health outcomes for a total of 631 risk-outcome pairs. Pairs were included on the basis of data-driven determination of a risk-outcome association. Age-sex-location-year-specific estimates were generated at global, regional, and national levels. Our approach followed the comparative risk assessment framework predicated on a causal web of hierarchically organised, potentially combinative, modifiable risks. Relative risks (RRs) of a given outcome occurring as a function of risk factor exposure were estimated separately for each risk-outcome pair, and summary exposure values (SEVs), representing risk-weighted exposure prevalence, and theoretical minimum risk exposure levels (TMRELs) were estimated for each risk factor. These estimates were used to calculate the population attributable fraction (PAF; ie, the proportional change in health risk that would occur if exposure to a risk factor were reduced to the TMREL). The product of PAFs and disease burden associated with a given outcome, measured in disability-adjusted life-years (DALYs), yielded measures of attributable burden (ie, the proportion of total disease burden attributable to a particular risk factor or combination of risk factors). Adjustments for mediation were applied to account for relationships involving risk factors that act indirectly on outcomes via intermediate risks. Attributable burden estimates were stratified by Socio-demographic Index (SDI) quintile and presented as counts, age-standardised rates, and rankings. To complement estimates of RR and attributable burden, newly developed burden of proof risk function (BPRF) methods were applied to yield supplementary, conservative interpretations of risk-outcome associations based on the consistency of underlying evidence, accounting for unexplained heterogeneity between input data from different studies. Estimates reported represent the mean value across 500 draws from the estimate's distribution, with 95% uncertainty intervals (UIs) calculated as the 2·5th and 97·5th percentile values across the draws.
Citation impact
- FWCI
- 1236.17
- Percentile
- 100%
- References
- 62
Authors
1795Topics & keywords
- Burden of disease
- Disease burden
- Disease
- Environmental health
- Medicine
- Pathology
Funding
- UDU.S. Department of Defense
- USUnited States Agency for International Development
- BABill and Melinda Gates FoundationAward: OPP1152504
- AHAmerican Heart AssociationAward: COVID-19
- AAmgen
- ISInternational Society for Infectious Diseases
- PPfizer
- SSanofi
- WHWorld Health OrganizationAward: COVID-19
- ISInternational Society of Travel Medicine
- BPBloomberg Philanthropies
- BGBGI Group
- DODepartment of Health and Social Care
- ECEuropean CommissionAwards: CIT5-CT-2005-028857, 261982, P01_AG08291, SHARE-I3: RII-CT-2006-062193, SHARE M4, SHARE-I3, QLK6-CT-2001-00360, R21_AG025169, 211909, CIT4-CT-2006-028812, N°211909, IAG_BSR06-11, U01_AG09740-13S2, Y1-AG-4553-01, RRF-2.3.1-21-2022-00006, OGHA_04-064, COVID-19, P01_AG005842, RII-CT-2006-062193, N°227822, N°261982, 227822, P30_AG12815, HHSN271201300071C
- UOUniversity of Tasmania
- NRNational Research FoundationAward: 2016-2017
- SASouth African Medical Research Council
- UOUniversity of Pretoria
- DFDeutsche Forschungsgemeinschaft
- MUMonash University
- BFBundesministerium für Bildung und ForschungAwards: P30_AG12815, HHSN271201300071C, RII-CT-2006-062193, P01_AG08291, IAG_BSR06-11, CIT5-CT-2005-028857, OGHA_04-064, QLK6-CT-2001-00360, 261982, 227822, R21_AG025169, 211909, U01_AG09740-13S2, Y1-AG-4553-01, CIT4-CT-2006-028812, P01_AG005842
- KSKing Saud UniversityAward: RSP-2024 R47
- MOMinistry of Education
- FCFondazione Cariplo
- GDGeneralitat de CatalunyaAward: 2017-2018
- MOMinistry of Trade, Industry and EnergyAwards: P0017805, No. P0017805
- MDMinistero della SaluteAward: 2018-
- QGQueensland Government
- KIKorea Institute for Advancement of TechnologyAwards: No. P0017805, P0017805
- NRNational Research Foundation of KoreaAwards: NRF-2023S1A3A2A05095298, 2015-2016, 2013-14, 2016-2017
- MMax-Planck-GesellschaftAwards: Y1-AG-4553-01, R21_AG025169, P30_AG12815, P01_AG08291, P01_AG005842, 227822, CIT4-CT-2006-028812, HHSN271201300071C, OGHA_04-064, 261982, IAG_BSR06-11, CIT5-CT-2005-028857, RII-CT-2006-062193, 211909, QLK6-CT-2001-00360, U01_AG09740-13S2
- SSocialdepartementet
- MOMinistry of Health and Family Welfare
- AAAddis Ababa University
- HFHellenic Foundation for Research and Innovation
- HLH. Lundbeck A/S
- UPUniversitat Politècnica de Catalunya
- NSNational Science and Technology Council
- AAllergan
- SGSanofi Genzyme
- MRMedical Research CouncilAwards: MR/M015084/1, COVID-19
- NHNational Health and Medical Research Council
- JAJapan Aerospace Exploration Agency
- EREuropean Regional Development Fund
- NINorwegian Institute of Public Health